TUDCA

Tauroursodeoxycholic acid (TUDCA) is a naturally occurring hydrophilic bile acid formed by taurine conjugation of ursodeoxycholic acid (UDCA), identified in bear bile in 1902 and used in traditional Chinese medicine for centuries prior to its modern pharmacological characterization. The compound functions principally as a chemical chaperone that alleviates endoplasmic reticulum (ER) stress by stabilizing the unfolded protein response (UPR) through modulation of the three canonical ER stress sensor pathways: PERK/eIF2alpha/ATF4, IRE1alpha/XBP1, and ATF6. Beyond ER stress modulation, TUDCA exerts potent anti-apoptotic activity through prevention of Bax translocation to mitochondrial membranes, inhibition of cytochrome c release, and activation of the PI3K/Akt survival pathway. The compound stabilizes mitochondrial membrane potential, reduces reactive oxygen species production, suppresses NF-kappaB-mediated proinflammatory cytokine release, and activates the nuclear receptor FXR and the membrane receptor TGR5. TUDCA crosses the blood-brain barrier and has demonstrated neuroprotective activity in preclinical models of Alzheimer's disease (APP/PS1 transgenic mice, reducing amyloid-beta deposition and rescuing spatial memory), Parkinson's disease (MPTP model, preventing dopaminergic neuronal loss), Huntington's disease (3-nitropropionic acid model, preserving striatal mitochondria), amyotrophic lateral sclerosis (SOD1 transgenic mice), retinal degeneration (multiple retinitis pigmentosa models), and ischemic stroke (reducing infarct volume by approximately 50 percent). The clinical evidence base includes Phase II trials in amyotrophic lateral sclerosis demonstrating a favorable responder rate (87 percent versus 43 percent on placebo at 1 gram in the published literature for 54 weeks in the Elia 2016 trial), a randomized controlled trial in obese insulin-resistant adults demonstrating a 30 percent improvement in hepatic and muscle insulin sensitivity at 1750 mg daily for 4 weeks, multiple trials in cholestatic liver disease demonstrating 40 to 51 percent reductions in liver enzymes, a Phase I/II trial in progressive multiple sclerosis demonstrating safety and immunological biomarker effects, and the Phase II CENTAUR trial of the combination product AMX0035 (TUDCA plus sodium phenylbutyrate) in ALS, which received accelerated FDA approval in September 2022 but was withdrawn from the market in October 2024 following the failure of the confirmatory Phase III PHOENIX trial to meet primary or secondary endpoints. A separate European Phase III trial (TUDCA-ALS) of TUDCA monotherapy in 337 ALS patients similarly failed to demonstrate efficacy at 18 months. The compound has been licensed for the treatment of cholestatic liver disease and cholesterol gallstones in several European and Asian jurisdictions since 1991 and maintains a favorable safety profile, with the principal adverse events being mild gastrointestinal effects (diarrhea in approximately 14 percent, abdominal pain in approximately 6 percent). This monograph reviews the chemistry, endogenous biosynthesis, and structural pharmacology of TUDCA; the multi-target cytoprotective mechanism spanning ER stress, mitochondrial stabilization, anti-apoptosis, and anti-inflammatory pathways; the comprehensive pharmacokinetic record including hepatic first-pass metabolism and blood-brain barrier penetration; the clinical evidence base across hepatobiliary, neurodegenerative, metabolic, retinal, and inflammatory indications; the reconstitution, sourcing, and stack-interaction considerations for laboratory and research applications; and a comparative assessment of five cytoprotective and neuroprotective candidates against TUDCA on five competency standards.